Innovent Biologics, Inc. announced revenue results for the fourth quarter of 2022. In the fourth quarter of 2022, the Company achieved a total product revenue of approximately RMB 1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.15 HKD | +1.56% | +17.92% | -8.42% |
04-17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
04-02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.42% | 8.12B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 1801 Stock
- News Innovent Biologics, Inc.
- Innovent Biologics, Inc. Announces Revenue Results for the Fourth Quarter of 2022